Molybdenum Disubstituted Alkylidene Complexes

Through relatively straightforward techniques that begin with Mo(NAr)(CH-t-Bu)[OCMe(CF3)2]2 (Ar = 2,6-i-Pr2C6H3), we have prepared Mo(NAr)(CMePh)(OMesityl)2, [Mo(NAr)(CMePh)(OC6F5)2]2, Mo(NAr)(CMePh)(OC6F5)2(MeCN), Mo(NAr)(CMePh)(OC6F5)2(bipyridyl), Mo(NAr)(CMePh)(Cl)2(bipyridyl), Mo(NAr)(CMePh)(Cl)(OHMT)(MeCN) (OHMT = O-2,6-(2,4,6-Me3C6H2)2C6H3), and Mo(NAr)(CMePh)(Pyrrolide)(OHMT). X-ray studies reveal that in five compounds the alkylidene isomer (A) is that in which the phenyl group in the alkylidene points toward the imido nitrogen. In Mo(NAr)(CMePh)(OC6F5)2(MeCN) the isomer in which the methyl group points toward the imido nitrogen (isomer B) has cocrystallized with isomer A (12%). In two 14e compounds that contain isomer A, the Mo═C-C angles differ by 30-36°, consistent with a Mo...C-Hβ agostic interaction. Several of the complexes reported here react readily with ethylene, 1-decene, or cyclooctene to give the expected products, thus confirming their viability as initiators or intermediates in metathesis reactions

Syntheses of Molybdenum and Tungsten Imido Alkylidene Complexes that Contain a Bidentate Oxo/Thiolato Ligand

3,3′,5,5′-Tetra-tert-butyl-2′-sulfanyl[1,1′-biphenyl]-2-ol (H2[tBu4OS]) was prepared in 24 % yield overall from the analogous biphenol using standard techniques. Addition of H2[tBu4OS] to Mo(NAr)(CHCMe2Ph)(2,5-dimethylpyrrolide)2 led to formation of Mo(NAr)(CHCMe2Ph)[tBu4OS], which was trapped with PMe3 to give Mo(NAr)(CHCMe2Ph)[tBu4OS](PMe3) (1(PMe3)). An X-ray crystallographic study of 1(PMe3) revealed that two structurally distinct square pyramidal molecules are present in which the alkylidene ligand occupies the apical position in each. Both 1(PMe3)A and 1(PMe3)B are disordered. Mo(NAd)(CHCMe2Ph)(tBu4OS)(PMe3) (2(PMe3); Ad=1-adamantyl) and W(NAr)(CHCMe2Ph)(tBu4OS)(PMe3) (3(PMe3)) were prepared using analogous approaches. 1(PMe3) reacts with ethylene (1 atm) in benzene within 45 minutes to give an ethylene complex Mo(NAr)(tBu4OS)(C2H4) (4) that is isolable and relatively stable toward loss of ethylene below 60 °C. An X-ray study shows that the bond distances and angles for the ethylene ligand in 4 are like those found for bisalkoxide ethylene complexes of the same general type. Complex 1(PMe3) in the presence of one equivalent of B(C6F5)3 catalyzes the homocoupling of 1-decene, allyltrimethylsilane, and allylboronic acid pinacol ester at ambient temperature. 1(PMe3), 2(PMe3), and 3(PMe3) all catalyze the ROMP of rac-endo,exo-5,6-dicarbomethoxynorbornene (rac-DCMNBE) in the presence of B(C6F5)3, but the polyDCMNBE that is formed has a random structure

Catalytic living ring-opening metathesis polymerization

In living ring-opening metathesis polymerization (ROMP), a transition-metal–carbene complex polymerizes ring-strained olefins with very good control of the molecular weight of the resulting polymers. Because one molecule of the initiator is required for each polymer chain, however, this type of polymerization is expensive for widespread use. We have now designed a chain-transfer agent (CTA) capable of reducing the required amount of metal complex while still maintaining full control over the living polymerization process. This new method introduces a degenerative transfer process to ROMP. We demonstrate that substituted cyclohexene rings are good CTAs, and thereby preserve the ‘living’ character of the polymerization using catalytic quantities of the metal complex. The resulting polymers show characteristics of a living polymerization, namely narrow molecular-weight distribution, controlled molecular weights and block copolymer formation. This new technique provides access to well- defined polymers for industrial, biomedical and academic use at a fraction of the current costs and significantly reduced levels of residual ruthenium catalyst

MAPK pathway activation in pilocytic astrocytoma

Pilocytic astrocytoma (PA) is the most common tumor of the pediatric central nervous system (CNS). A body of research over recent years has demonstrated a key role for mitogen-activated protein kinase (MAPK) pathway signaling in the development and behavior of PAs. Several mechanisms lead to activation of this pathway in PA, mostly in a mutually exclusive manner, with constitutive BRAF kinase activation subsequent to gene fusion being the most frequent. The high specificity of this fusion to PA when compared with other CNS tumors has diagnostic utility. In addition, the frequency of alteration of this key pathway provides an opportunity for molecularly targeted therapy in this tumor. Here, we review the current knowledge on mechanisms of MAPK activation in PA and some of the downstream consequences of this activation, which are now starting to be elucidated both in vitro and in vivo, as well as clinical considerations and possible future directions